Navigation Links
Proposed Settlement Will Make Up to $28 Million Available to Individuals Who Purchased and Companies That Reimbursed for Paxil CR(R)
Date:3/25/2009

WASHINGTON, March 25 /PRNewswire-USNewswire/ -- Persons who purchased or paid for (in whole or in part) Paxil CR(R) and insurance companies and other entities that reimbursed for (in whole or in part) Paxil CR(R) in the United States and its territories may be eligible for relief as part of a $28 million Proposed Settlement. The lawsuit claims that the Paxil CR(R) tablets GlaxoSmithKline ("GSK") manufactured between April 1, 2002 and March 4, 2005 contained a manufacturing defect that caused some of the tablets to split apart. GSK denies all of these claims and any liability.

If approved, the Proposed Settlement will provide up to $28 million to settle the claims in the lawsuit. Some of this money will be paid to insurance companies and other entities that made reimbursements for (in whole or in part) Paxil CR(R) and some of this money will be paid to consumers who purchased or paid for (in whole or in part) Paxil CR(R). The recovery available to insurance companies and other Third-Party Payors ("TPPs") will be based on their number of covered lives as of December 31, 2004. Consumer class members' recovery will be based on the number of Paxil CR(R) tablets that they paid for or purchased, up to $150, that were defective in that they were split before they were removed from the container in which they were purchased.

Potential Class Members do not need to do anything to stay in the class. However, they must submit a Claim Form if they wish to obtain money from the Proposed Settlement. Claim Forms are available by visiting the website www.SimonetPaxilCRSettlement.com or by calling 1-866-458-3186. Claim Forms must be postmarked by August 10, 2009.

Class Members wishing to exclude themselves from or object to the Proposed Settlement must do so as outlined in the Notice of Proposed Class Action Settlement, available by visiting the informational website www.SimonetPaxilCRSettlement.com or by calling 1-866-458-3186. Those wishing to exclude themselves from the Proposed Settlement must do so no later than May 15, 2009. Those wishing to object to the Proposed Settlement must do so no later than July 1, 2009. A Class Member must remain in the Class in order to object.

The Court has appointed the law firms Strange & Carpenter and Salas & Co., L.C. to represent the proposed Class. The Court will hold a Final Approval Hearing on July 10, 2009. At that time, the Court will consider the motion for attorneys' fees and expenses, and it will decide whether the Proposed Settlement is fair, reasonable and adequate. All potential Class Members are encouraged to visit www.SimonetPaxilCRSettlement.com or call the Simonet Paxil CR(R) Settlement Administrator at 1-866-458-3186 to determine if they are a Class Member and obtain information about their legal rights, how to file a Claim, or how to object or exclude themselves.


'/>"/>
SOURCE Simonet Paxil CR(R) Settlement Administrator
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Physician Skin Care Specialist Says Proposed New Rules for Sunscreen Products Will Better Protect the Public
3. Kyphon Announces Special Meeting Date to Vote on Proposed Medtronic Merger
4. Hologic Sets Special Meeting of Stockholders to Vote on Proposed Merger with Cytyc Corporation
5. Microtek Medical Receives Early Termination of Hart-Scott-Rodino Act Waiting Period for Its Proposed Acquisition by Ecolab
6. Screening Proposed for Childhood Cholesterol Levels
7. More than 10,000 Medicare Patients in Montana Could Be Hit by Proposed Cuts to Home Oxygen Therapy; Access to Power Wheelchairs Would Also Decrease
8. Pelosi Statement on Proposed Entitlement Task Force
9. Paramount Acquisition Corp. Announces Record Date of October 1, 2007 for Proposed Acquisition of Chem Rx
10. Paramount Acquisition Corp. Files Amendment to Preliminary Proxy Statement for Proposed Acquisition of Chem Rx
11. AARP Calls on State Regulators to Reject Proposed Settlement of TXU Buyout
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... California (PRWEB) , ... June 27, 2016 , ... "FCPX ... fully customizable inside of Final Cut Pro X," said Christina Austin - CEO of ... unique style. Final Cut Pro X users can now reveal the media ...
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
Breaking Medicine Technology: